Noven Pharmaceuticals said it expects to begin manufacturing a patch to treat attention deficit hyperactivity disorder in children aged 6 to 12 years. Two years ago, the Food and Drug Administration denied a Noven (NASDAQ: NOVN) application to make the patch. But, in a new application earlier this month, an FDA panel voted in favor of the efficacy and safety of the product. Daytrana is licensed globally to Shire. FDA review is scheduled to conclude Dec. 28.
The South Florida Business Journal (http://southflorida.bizjournals.com/southflorida/stories/2005/12/12/daily35.html)